Primary prevention of cardiovascular disease: a cost-effectiveness comparison

被引：0
|
作者：
Franco, O
De Laet, C
Der Kinderen, A
Peeters, A
Bonneux, L
机构：
[1] Erasmus MC, Rotterdam, Netherlands
[2] Utrecht Med Ctr, JulCtr, Utrecht, Netherlands
来源：
EUROPEAN HEART JOURNAL | 2004年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：122 / 122
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of statins for primary prevention of coronary heart disease in Japan
    Ikeda, Shunya
    Kobayashi, Makoto
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S225 - S226
  • [42] Cost-Effectiveness of Primary Prevention Strategies for Nephrolithiasis
    Lotan, Yair
    Pearle, Margaret S.
    [J]. JOURNAL OF UROLOGY, 2011, 186 (02): : 550 - 555
  • [43] COST-EFFECTIVENESS OF TICLOPIDINE IN PRIMARY STROKE PREVENTION
    HUSE, DM
    LACEY, MJ
    OSTER, G
    EPSTEIN, AM
    [J]. CLINICAL RESEARCH, 1990, 38 (02): : A257 - A257
  • [44] A model for undertaking effectiveness and cost-effectiveness analyses of primary preventive strategies in cardiovascular disease
    Liew, Danny
    Lim, Stephen S.
    Bertram, Melanie
    McNeil, John J.
    Vos, Theo
    [J]. EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2006, 13 (04): : 515 - 522
  • [45] Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis
    Gaziano, Thomas A.
    Opie, Lionel H.
    Weinstein, Milton C.
    [J]. LANCET, 2006, 368 (9536): : 679 - 686
  • [46] The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective
    Zomer, Ella
    Liew, Danny
    Tonkin, Andrew
    Trauer, James M.
    Ademi, Zanfina
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2019, 285 : 1 - 5
  • [47] Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk
    Greving, Jacoba P.
    Buskens, Erik
    Koffijberg, Hendrik
    Algra, Ale
    [J]. CIRCULATION, 2008, 117 (22) : 2875 - 2883
  • [48] COST-EFFECTIVENESS ANALYSIS OF AN ADJUSTED POLYGENIC RISK SCORE IN CARDIOVASCULAR DISEASE PREVENTION
    Hatziandreou, E.
    Panagiotou, N.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S81 - S81
  • [49] A cost-effectiveness analysis of low-dose Aspirin in the primary prevention of cardiovascular disease in four European countries
    Lamotte, M
    Annemans, L
    Evers, T
    Kubin, M
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A98 - A99
  • [50] Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease
    Pandya, Ankur
    Sy, Stephen
    Cho, Sylvia
    Weinstein, Milton C.
    Gaziano, Thomas A.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (02): : 142 - 150
12345